Optimize
Everything.

Research timelines vary by compound. Retatrutide researchers typically note appetite and metabolic changes in weeks 1–2. MOTS-C energy-related observations are commonly reported within 5–7 days. Tesamorelin sleep quality observations typically emerge by weeks 2–3. Body composition research findings generally appear weeks 6–10. Individual results vary — these are research reference points only, not clinical outcomes.

Most research peptides are administered via subcutaneous injection using 31G insulin pins — minimally invasive and standard in research settings. Slupp-332 is the exception, available in oral capsule form. Administration method, site rotation, and timing are all detailed in the Kinetic Performance Playbook. Always consult a licensed healthcare provider before beginning any research protocol.

Research suggests peptide compounds support the body's natural biological systems rather than replacing them. Body composition changes observed during a research cycle are generally maintained through proper off-cycle periods. The standard framework is a research cycle followed by a structured off-cycle to allow receptor reset before the next cycle begins.

Best practice is to begin with 2–3 research compounds maximum, introducing one new compound every 2 weeks. This allows researchers to clearly identify which compound is producing which observed effect — or any adverse responses. Compound stacking is addressed in detail during your free research consultation.

Most standard workplace and sports drug panels do not screen for research peptides. However, WADA-regulated athletes should verify their specific research compounds against their governing body's prohibited substance list before beginning any protocol. This is your responsibility as the researcher.

In the US, peptide compounds are sold as research chemicals for laboratory and analytical use only. They are not FDA-approved for human use and are not intended to diagnose, treat, cure, or prevent any disease. Kinetic Performance Group is not a medical provider. Always consult a licensed healthcare provider before beginning any research protocol.

Early-cycle observations commonly documented include mild GI adjustment (weeks 2–4 on GLP-1 compounds), reduced appetite signaling, transient water retention in week 1, and enhanced sleep depth from GH-class compounds. Fatigue or cognitive fog may indicate a dose adjustment is needed. Full research observation reference is available in the Kinetic Performance Playbook.

A free 30-minute 1:1 research consultation covering your research objectives, health background, and lifestyle context. You receive a custom research protocol reference, compound administration schedule, and research framework — all for educational purposes only. All compounds discussed are for research use only, not for human therapeutic application.